Eurobio Scientific (ALERS) | Financial Analysis & Statements
Eurobio Scientific S.A. | Mid-cap | Healthcare
Eurobio Scientific S.A. | Mid-cap | Healthcare
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
154.9M
Gross Profit
72.0M
46.44%
Operating Income
9.8M
6.32%
Net Income
4.0M
2.58%
EPS (Diluted)
€0.39
Balance Sheet Metrics
Total Assets
257.2M
Total Liabilities
78.3M
Shareholders Equity
178.9M
Debt to Equity
0.44
Cash Flow Metrics
Operating Cash Flow
1.9M
Free Cash Flow
13.4M
Revenue & Profitability Trend
Eurobio Scientific Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 154.9M | 130.6M | 152.9M | 185.3M | 189.2M |
| Cost of Goods Sold | 83.0M | 73.2M | 81.7M | 82.5M | 78.5M |
| Gross Profit | 72.0M | 57.5M | 71.2M | 102.8M | 110.7M |
| Operating Expenses | 53.6M | 39.4M | 34.5M | 27.9M | 24.7M |
| Operating Income | 9.8M | 10.1M | 30.9M | 70.1M | 81.2M |
| Pre-tax Income | 6.3M | 7.0M | 29.7M | 71.3M | 80.9M |
| Income Tax | 2.3M | 2.1M | 4.7M | 10.8M | 7.4M |
| Net Income | 4.0M | 4.8M | 24.9M | 60.5M | 73.5M |
| EPS (Diluted) | €0.39 | €0.43 | €2.20 | €5.57 | €6.53 |
Income Statement Trend
Eurobio Scientific Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 89.6M | 143.9M | 148.7M | 173.6M | 135.2M |
| Non-Current Assets | 167.6M | 172.4M | 182.0M | 36.3M | 37.1M |
| Total Assets | 257.2M | 316.3M | 330.7M | 209.9M | 172.3M |
| Liabilities | |||||
| Current Liabilities | 44.1M | 52.9M | 57.3M | 36.1M | 48.0M |
| Non-Current Liabilities | 34.2M | 88.3M | 100.4M | 12.9M | 16.5M |
| Total Liabilities | 78.3M | 141.2M | 157.7M | 49.0M | 64.5M |
| Equity | |||||
| Total Shareholders Equity | 178.9M | 175.2M | 173.0M | 160.9M | 107.8M |
Balance Sheet Composition
Eurobio Scientific Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 4.0M | 4.8M | 24.9M | 60.5M | 73.5M |
| Operating Cash Flow | 1.9M | 15.0M | 35.0M | 57.3M | 45.8M |
| Investing Activities | |||||
| Capital Expenditures | -3.1M | -2.2M | -315.0K | -1.7M | -2.3M |
| Investing Cash Flow | -13.2M | -6.7M | -132.5M | -1.7M | -4.5M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | -67.6M | -19.3M | 85.1M | -21.6M | 9.0M |
| Free Cash Flow | 13.4M | 22.7M | 40.2M | 64.1M | 52.6M |
Cash Flow Trend
Eurobio Scientific Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
64.74
Forward P/E
22.75
Price to Book
1.42
Price to Sales
1.64
PEG Ratio
22.75
Profitability Ratios
Profit Margin
2.58%
Operating Margin
16.08%
Return on Equity
2.26%
Return on Assets
4.34%
Financial Health
Current Ratio
2.03
Debt to Equity
5.46
Beta
0.43
Per Share Data
EPS (TTM)
€0.39
Book Value per Share
€17.82
Revenue per Share
€15.10
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| alers | 253.4M | 64.74 | 1.42 | 2.26% | 2.58% | 5.46 |
| Affluent Medical | 53.3M | -3.55 | 1.73 | -48.69% | -275.50% | 0.54 |
| Carmat S.A | 24.8M | - | - | 100.52% | -336.56% | -1.13 |
| Median Technologies | 25.6M | -1.02 | - | 74.31% | -109.93% | -0.98 |
| Novacyt S.A | 34.9M | -0.82 | 0.72 | -57.28% | -212.73% | 24.81 |
| Diagnostic Medical | 24.2M | -8.64 | 1.96 | -20.20% | -5.90% | 141.76 |
Financial data is updated regularly. All figures are in the company's reporting currency.